The lawsuit claims that three major healthcare companies were pushing up the price of insulin by 1,200 percent.
The Federal Trade Commission said three top pharmacy suppliers made profits of 7,700 percent on a lifesaving hypertension ...
The FTC report found that from 2017 to 2022, three PBMs—UnitedHealth Group's Optum, CVS Health's CVS Caremark and Cigna's ...
On Tuesday, the Federal Trade Commission released its second interim staff report on prescription drug middlemen. The report ...
From 2017 to 2022, the companies marked up prices at their pharmacies by hundreds or thousands of percent, netting them $7.3 billion in revenue.
The Federal Trade Commision (FTC) found prescription benefits managers like UnitedHealth's OptumRX have gained $7.3B from ...
Evercore ISI raised the firm’s price target on CVS Health (CVS) to $65 from $60 and keeps an Outperform rating on the shares. Given 2025 will ...
Between 2017 and 2022, UnitedHealth Group’s Optum, Cigna’s Express Scripts and CVS Health’s CVS Caremark marked up their ...
(Bloomberg) -- Units of CVS Health Corp., Cigna Group and UnitedHealth Group ... bringing in more than $7.3 billion in “excess” revenue over six years, the Federal Trade Commission said in a report on ...